Physician profile
Peter A Dawson
NPI 1407141492
$1,135.32
in general payments reported to CMS, 2019-2025
10 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $123 · 2021: $70.44 · 2022: $72.64 · 2023: $29.17 · 2024: $268 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $345.63 | 2023-2025 | Botox |
| Allergan, INC. | $283.68 | 2019-2022 | |
| Merz North America, INC. | $118.75 | 2019-2020 | |
| Grt US Holding, INC. | $89.79 | 2020-2022 | |
| Microtransponder, INC. | $86.41 | 2024 | |
| Sanofi-Aventis U.S. LLC | $71.20 | 2019-2020 | |
| Spr Therapeutics, INC | $70.57 | 2019 | |
| Pfizer INC. | $26.29 | 2020-2021 | |
| Averitas Pharma INC. | $23.94 | 2024 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $19.06 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.